Table 4.
Subgroup analyses in patients with and without chronic obstructive pulmonary disease.
| Exposure to human insulin | Case number | Incident lung cancer | % | Person-years | Incidence rate (per 100,000 person-years) | Adjusted hazard ratio | 95% Confidence interval | P |
|---|---|---|---|---|---|---|---|---|
| PATIENTS WITH COPD | ||||||||
| Never-users | 103,867 | 2,613 | 2.52 | 495,698.33 | 527.14 | 1.000 | ||
| Ever-users | 40,981 | 1,070 | 2.61 | 172,564.33 | 620.06 | 1.546 | (1.430–1.673) | <0.0001 |
| PATIENTS WITHOUT COPD | ||||||||
| Never-users | 747,030 | 11,064 | 1.48 | 3,865,528.92 | 286.22 | 1.000 | ||
| Ever-users | 115,739 | 1,937 | 1.67 | 535,877.00 | 361.46 | 1.550 | (1.469–1.635) | <0.0001 |
Hazard ratios are adjusted for all variables in Table 1. COPD, chronic obstructive pulmonary disease. P interaction between insulin and COPD = 0.2035.